TY - JOUR
T1 - Outcome-based reimbursement in Central-Eastern Europe and Middle-East
AU - Ádám, Ildikó
AU - Callenbach, Marcelien
AU - Németh, Bertalan
AU - Vreman, Rick A
AU - Tollin, Cecilia
AU - Pontén, Johan
AU - Dawoud, Dalia
AU - Elvidge, Jamie
AU - Crabb, Nick
AU - van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh
AU - Pisters-van Roy, Anke
AU - Vincziczki, Áron
AU - Almomani, Emad
AU - Vajagic, Maja
AU - Oner, Z Gulsen
AU - Matni, Mirna
AU - Fürst, Jurij
AU - Kahveci, Rabia
AU - Goettsch, Wim G
AU - Kaló, Zoltán
N1 - Copyright © 2022 Ádám, Callenbach, Németh, Vreman, Tollin, Pontén, Dawoud, Elvidge, Crabb, van Waalwijk van Doorn-Khosrovani, Pisters-van Roy, Vincziczki, Almomani, Vajagic, Oner, Matni, Fürst, Kahveci, Goettsch and Kaló.
PY - 2022/9/23
Y1 - 2022/9/23
N2 - Outcome-based reimbursement models can effectively reduce the financial risk to health care payers in cases when there is important uncertainty or heterogeneity regarding the clinical value of health technologies. Still, health care payers in lower income countries rely mainly on financial based agreements to manage uncertainties associated with new therapies. We performed a survey, an exploratory literature review and an iterative brainstorming in parallel about potential barriers and solutions to outcome-based agreements in Central and Eastern Europe (CEE) and in the Middle East (ME). A draft list of recommendations deriving from these steps was validated in a follow-up workshop with payer experts from these regions. 20 different barriers were identified in five groups, including transaction costs and administrative burden, measurement issues, information technology and data infrastructure, governance, and perverse policy outcomes. Though implementing outcome-based reimbursement models is challenging, especially in lower income countries, those challenges can be mitigated by conducting pilot agreements and preparing for predictable barriers. Our guidance paper provides an initial step in this process. The generalizability of our recommendations can be improved by monitoring experiences from pilot reimbursement models in CEE and ME countries and continuing the multistakeholder dialogue at national levels.
AB - Outcome-based reimbursement models can effectively reduce the financial risk to health care payers in cases when there is important uncertainty or heterogeneity regarding the clinical value of health technologies. Still, health care payers in lower income countries rely mainly on financial based agreements to manage uncertainties associated with new therapies. We performed a survey, an exploratory literature review and an iterative brainstorming in parallel about potential barriers and solutions to outcome-based agreements in Central and Eastern Europe (CEE) and in the Middle East (ME). A draft list of recommendations deriving from these steps was validated in a follow-up workshop with payer experts from these regions. 20 different barriers were identified in five groups, including transaction costs and administrative burden, measurement issues, information technology and data infrastructure, governance, and perverse policy outcomes. Though implementing outcome-based reimbursement models is challenging, especially in lower income countries, those challenges can be mitigated by conducting pilot agreements and preparing for predictable barriers. Our guidance paper provides an initial step in this process. The generalizability of our recommendations can be improved by monitoring experiences from pilot reimbursement models in CEE and ME countries and continuing the multistakeholder dialogue at national levels.
KW - health technology assessment
KW - managed entry agreement
KW - outcome-based agreement
KW - outcome-based reimbursement
KW - pay-for-performance
KW - pricing
KW - reimbursement
KW - value-based pricing
UR - http://www.scopus.com/inward/record.url?scp=85140048094&partnerID=8YFLogxK
U2 - 10.3389/fmed.2022.940886
DO - 10.3389/fmed.2022.940886
M3 - Article
C2 - 36213666
SN - 2296-858X
VL - 9
SP - 1
EP - 11
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 940886
ER -